
Overview
Dr. Channing J. Paller is a medical oncologist at Sibley Memorial Hospital and a professor of oncology at the Johns Hopkins University School of Medicine. She practices out of the Prostate Cancer Multidisciplinary Clinic at Sibley Memorial Hospital in Washington, D.C., and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, MD. Dr. Paller has expertise in prostate, bladder, kidney, and testicular cancer. Dr. Paller earned her medical degree from Harvard Medical School and completed a residency in internal medicine, followed by a fellowship in hematology and oncology at Johns Hopkins University School of Medicine. In addition, Dr. Paller completed a rotation with the chief of the Investigational Drug Branch at the National Cancer Institute (NCI) Cancer Therapy Evaluation Program and a rotation with the associate director for regulatory science in the Office of Oncology Drug Products at the Food and Drug Administration. She also completed rotations at the Weizmann Institute of Israel’s Department of Biological Regulation and McCord Hospital in South Africa, where she participated in the Harvard AIDS project. In 2016, Dr. Paller was one of only five oncologists awarded the NCI Mentored Patient-Oriented Research Career Development Award. In 2015, she received the 2015 Passano Clinician Scientist Award for early-stage research that is already making a contribution to science. Earlier in her career, she was selected for both a 2011-2012 Young Investigator Award by the American Society of Clinical Oncology and for the 2011-12 Eastern Cooperative Oncology Group Paul Carbone Award. Dr. Paller is a member of the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Paller’s research focuses on evaluating new therapies for prostate cancer, particularly combination therapies that engage the immune system. She is the principal investigator on two multi-site clinical trials and was the first author on the NCI Investigational Drug Steering Committee publication, “Consensus Recommendations on the Phase I Combination Clinical Trials of the Clinical Trial Design Task Force.” Dr. Paller was the chair for the oral abstract session on genitourinary cancer at the 2015 Annual Meeting of the American Society of Clinical Oncology and she is currently funded by an NCI immunotherapy grant to look at combination therapies that link standard of care therapy with inhibition of transforming growth factor beta in prostate cancer. She is also opening trials of vitamin C with chemotherapy in prostate cancer and of mistletoe in all solid tumors.
Dr. Paller is rated as an Experienced provider by MediFind in the treatment of Bone Tumor. Her top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, Hormone Replacement Therapy (HRT), and Prostatectomy.
Her clinical research consists of co-authoring 132 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles in the study of Bone Tumor.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MEDICARE MAPD
- OTHER COMMERCIAL
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
Building B, Washington, DC 20016
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
13 Clinical Trials
Skip Viragh Outpatient Cancer Center
Dr. Meyer will serve as the lead medical oncologist for adult sarcoma patients, and will focus on building the Adult Sarcoma and Connective Tissue Oncology Program. In collaboration with pediatric oncologist David Loeb, M.D., Ph.D., and orthopaedic surgeon Kristy Weber, M.D., Meyer will bring novel therapies to the clinic for sarcoma patients. Meyer received his bachelors and masters degrees in cell and molecular biology from Stanford University. From there, he joined the Medical Scientist Training Program at Baylor College of Medicine and earned his medical degree followed by a doctorate in immunology. Meyer completed his residency at the University of Maryland and served as chief resident in medicine from 2004-2005. Afterward, he joined our fellowship program in medical oncology and has been working in the laboratory of Jonathan Powell, M.D., Ph.D., on projects relating to the characterization of molecular regulatory pathways involved in T-cell activation and energy. As a third-year fellow, Meyer served as the chief fellow for our Training Programs in Hematology and Medical Oncology and he received a Young Investigator Award from the American Society of Clinical Oncology in 2010. Dr. Meyer is rated as a Distinguished provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Mesenchymoma, Undifferentiated Pleomorphic Sarcoma, Bone Tumor, and Ganglioneuroblastoma.
Dennis Priebat is a Hematologist Oncology specialist and an Oncologist in Washington, Washington, D.c.. Dr. Priebat is rated as a Distinguished provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Mesenchymoma, and Rhabdomyosarcoma Embryonal.
Johns Hopkins Outpatient Center
Daniel Lubelski is a fellowship-trained neurosurgeon with expertise in complex spine surgery and peripheral nerve surgery. He treats patients with spinal diseases and deformities, spine and nerve tumors, and brachial plexus injuries and other peripheral nerve injuries. Dr. Lubelski’s training in complex and robotic spine surgery, spinal oncology and peripheral nerve injuries allows him to comprehensively evaluate patients and develop custom treatment plans to address symptoms and improve patients’ quality of life. He prioritizes patient-centered care, effective communication and working in multidisciplinary collaboration to identify the best treatment. After obtaining his undergraduate degree at the City University of New York, Dr. Lubelski spent a year doing predoctoral research at the National Institutes of Health. He then obtained his medical degree from the Cleveland Clinic Lerner College of Medicine, and he performed stem cell tumor research as a Howard Hughes Medical Institute fellow. Dr. Lubelski went on to the Johns Hopkins University School of Medicine for a neurosurgery residency and an enfolded fellowship in peripheral nerve surgery. His postdoctoral training also included a fellowship in complex spine surgery and spinal oncology at Johns Hopkins, as well as a traveling fellowship with advanced training at the Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. Dr. Lubelski is a prolific researcher who focuses on patient quality of life and on using big data to develop individualized prediction models to determine optimal treatments tailored to each person. He has authored more than 200 peer-reviewed papers and numerous textbook chapters, has lectured nationally and internationally, and serves as a reviewer for the top neurosurgical journals. Dr. Lubelski is rated as a Distinguished provider by MediFind in the treatment of Bone Tumor. His top areas of expertise are Spinal Tumor, Chordoma, Spinal Stenosis, Spinal Fusion, and Laminectomy.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- Hormone Replacement Therapy (HRT)
- Prostate CancerDr. Paller isElite. Learn about Prostate Cancer.
- Distinguished
- Familial Prostate CancerDr. Paller isDistinguished. Learn about Familial Prostate Cancer.
- Advanced
- Muscle Invasive Bladder CancerDr. Paller isAdvanced. Learn about Muscle Invasive Bladder Cancer.
- Penile CancerDr. Paller isAdvanced. Learn about Penile Cancer.
- ProstatectomyDr. Paller isAdvanced. Learn about Prostatectomy.
- Renal Cell Carcinoma (RCC)Dr. Paller isAdvanced. Learn about Renal Cell Carcinoma (RCC).
- Experienced
- Adult Soft Tissue SarcomaDr. Paller isExperienced. Learn about Adult Soft Tissue Sarcoma.
- Bladder CancerDr. Paller isExperienced. Learn about Bladder Cancer.
- Bone TumorDr. Paller isExperienced. Learn about Bone Tumor.
- Breast CancerDr. Paller isExperienced. Learn about Breast Cancer.
- Chromophobe Renal Cell CarcinomaDr. Paller isExperienced. Learn about Chromophobe Renal Cell Carcinoma.
- Clear Cell SarcomaDr. Paller isExperienced. Learn about Clear Cell Sarcoma.

